Lanicemine

Drug Profile

Lanicemine

Alternative Names: ARL 15896; ARL 15896AR; ARR 15896; ARR 15896AR; BHV-5500; FPL 15896; FPL 15896AR

Latest Information Update: 27 Jun 2017

Price : $50

At a glance

  • Originator Astra Arcus USA
  • Class Antidepressants; Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders; Epilepsy; Stroke

Most Recent Events

  • 31 May 2017 Baylor College of Medicine and National Institute of Mental Health plan a phase I trial for Depression and Post traumatic stress disorders (NCT03166501)
  • 23 Jan 2007 Discontinued - Preclinical for CNS disorders in USA (unspecified route)
  • 17 Feb 2006 Discontinued - Preclinical for Epilepsy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top